AIM: To evaluate the clinical effects of the adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatment of generalized aggressive periodontitis (GAgP). METHODS:Thirty subjects were randomly assigned to receive scaling and root planing (SRP) alone or combined with MTZ (400 mg/TID) and AMX (500 mg/TID) for 14 days. Subjects were clinically monitored at baseline, 6 months and 1 year post-therapies. RESULTS: Both therapies led to a statistically significant improvement in all clinical parameters at 1 year post-therapy (p < 0.05). Subjects receiving MTZ plus AMX exhibited the deepest reductions in mean probing depth (PD) and gain in clinical attachment between baseline and 1 year post-therapy in the full-mouth analysis and in initially intermediate (PD 4-6 mm) and deep (PD ≥ 7 mm) sites (p < 0.01). In addition, the antibiotic group presented lower mean number of residual sites with PD ≥ 5 or 6 mm as well as fewer subjects still presenting nine or more sites with PD ≥ 5 mm or three or more sites with PD ≥ 6 mm at the end of the study period. CONCLUSION: The non-surgical treatment of GAgP is markedly improved by the adjunctive use of MTZ+AMX, up to 1 year post-treatment.
RCT Entities:
AIM: To evaluate the clinical effects of the adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatment of generalized aggressive periodontitis (GAgP). METHODS: Thirty subjects were randomly assigned to receive scaling and root planing (SRP) alone or combined with MTZ (400 mg/TID) and AMX (500 mg/TID) for 14 days. Subjects were clinically monitored at baseline, 6 months and 1 year post-therapies. RESULTS: Both therapies led to a statistically significant improvement in all clinical parameters at 1 year post-therapy (p < 0.05). Subjects receiving MTZ plus AMX exhibited the deepest reductions in mean probing depth (PD) and gain in clinical attachment between baseline and 1 year post-therapy in the full-mouth analysis and in initially intermediate (PD 4-6 mm) and deep (PD ≥ 7 mm) sites (p < 0.01). In addition, the antibiotic group presented lower mean number of residual sites with PD ≥ 5 or 6 mm as well as fewer subjects still presenting nine or more sites with PD ≥ 5 mm or three or more sites with PD ≥ 6 mm at the end of the study period. CONCLUSION: The non-surgical treatment of GAgP is markedly improved by the adjunctive use of MTZ+AMX, up to 1 year post-treatment.
Authors: Alexia Vinel; Antoine Al Halabi; Sébastien Roumi; Hélène Le Neindre; Pierre Millavet; Marion Simon; Constance Cuny; Jean-Sébastien Barthet; Pierre Barthet; Sara Laurencin-Dalicieux Journal: Adv Exp Med Biol Date: 2022 Impact factor: 2.622